Journal of Clinical Oncology, Vol 20, Issue 20
(October), 2002: 4209-4216
© 2002 American Society for Clinical Oncology
High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma
By Maura Massimino,
Filippo Spreafico,
Graziella Cefalo,
Riccardo Riccardi,
John David Tesoro-Tess,
Lorenza Gandola,
Daria Riva,
Antonio Ruggiero,
Laura Valentini,
Elena Mazza,
Lorenzo Genitori,
Concezio Di Rocco,
Piera Navarria,
Michela Casanova,
Andrea Ferrari,
Roberto Luksch,
Monica Terenziani,
Maria Rosa Balestrini,
Cesare Colosimo,
Franca Fossati-Bellani
From Pediatric Oncology, Radiodiagnostic E and Radiotherapy Unit, Istituto Nazionale Tumori; and Neurosurgery II and Development Pediatric Neurology Unit, Istituto Neurologico Carlo Besta, Milan; Pediatric Oncology and Neurosurgery Unit, Università Cattolica del Sacro Cuore–Policlinico Gemelli, Rome; Pediatric Neurosurgery Unit, Ospedale Infantile Regina Margherita, Torino; and Department Of Clinical Sciences and Bioimaging, Institute of Advanced Biomedical Technology G d A University, Chieti, Italy.
Address reprint requests to Maura Massimino, MD, Pediatric Oncology Unit, Istituto Nazionale Tumori, Via Venezian, 1 20133 Milano, Italy; email: massimino{at}istitutotumori.mi.it
PURPOSE: The aim of this study was to avoid radiotherapy and to induce an objective response in children with low-grade glioma (LGG) using a simple chemotherapy regimen based on cisplatin and etoposide.
PATIENTS AND METHODS: Thirty-four children (median age, 45 months) with unresectable LGG were treated with 10 monthly cycles of cisplatin (30 mg/m2/d on days 1 to 3) and etoposide (150 mg/m2/d on days 1 to 3). Tumor originated in the visual pathway in 29 patients, in the temporal lobe in two, in the frontal lobe in two, and in the spine in one. Eight children were affected by neurofibromatosis type 1. Objective tumor response and toxicity were evaluated by magnetic resonance imaging and neurologic and functional tests at 3-month intervals.
RESULTS: An objective response was obtained in 24 (70%) of 34 patients, whereas the others had stable disease. None of the children were electively irradiated. In 31 previously untreated children, overall survival was 100% and progression-free survival was 78% at 3 years, with a median follow-up of 44 months. Acute toxicity was unremarkable; 28% patients evaluated for acoustic neurotoxicity revealed a loss of perception of high frequencies.
CONCLUSION: Cisplatin and etoposide combined treatment is one of the most active regimens for LGG in children and allows avoidance of radiotherapy in the vast majority of patients.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. J. Sievert and M. J. Fisher
Pediatric Low-Grade Gliomas
J Child Neurol,
November 1, 2009;
24(11):
1397 - 1408.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. E. Merchant, L. E. Kun, S. Wu, X. Xiong, R. A. Sanford, and F. A. Boop
Phase II Trial of Conformal Radiation Therapy for Pediatric Low-Grade Glioma
J. Clin. Oncol.,
August 1, 2009;
27(22):
3598 - 3604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Merchant, H. M. Conklin, S. Wu, R. H. Lustig, and X. Xiong
Late Effects of Conformal Radiation Therapy for Pediatric Patients With Low-Grade Glioma: Prospective Evaluation of Cognitive, Endocrine, and Hearing Deficits
J. Clin. Oncol.,
August 1, 2009;
27(22):
3691 - 3697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sawamura, Y. Kamoshima, T. Kato, T. Tajima, and J. Tsubaki
Chemotherapy with Cisplatin and Vincristine for Optic Pathway/Hypothalamic Astrocytoma in Young Children
Jpn. J. Clin. Oncol.,
May 1, 2009;
39(5):
277 - 283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Lou, Q. Zhou, Y. Yin, C. Zhou, and Y. Shen
Inhibition of the met receptor tyrosine kinase signaling enhances the chemosensitivity of glioma cell lines to CDDP through activation of p38 MAPK pathway
Mol. Cancer Ther.,
May 1, 2009;
8(5):
1126 - 1136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. J. Becher, K. M. Peterson, S. Khatua, M. R. Santi, and T. J. MacDonald
IGFBP2 Is Overexpressed by Pediatric Malignant Astrocytomas and Induces the Repair Enzyme DNA-PK
J Child Neurol,
October 1, 2008;
23(10):
1205 - 1213.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Sawamura, K. Kamada, Y. Kamoshima, S. Yamaguchi, T. Tajima, J. Tsubaki, and T. Fujimaki
Role of surgery for optic pathway/hypothalamic astrocytomas in children
Neuro-oncol,
January 1, 2008;
10(5):
725 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C F Parsa and S Givrad
Pilocytic astrocytomas as hamartomas: implications for treatment
Br J Ophthalmol,
January 1, 2008;
92(1):
3 - 6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Via, E. Opocher, M. L. Pinello, M. Calderone, E. Viscardi, M. Clementi, P. A. Battistella, A. M. Laverda, L. Da Dalt, and G. Perilongo
Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program
Neuro-oncol,
October 1, 2007;
9(4):
430 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mora, O. Cruz, S. Gala, and R. Navarro
Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin
Neuro-oncol,
January 1, 2007;
9(1):
39 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Laithier, J. Grill, M.-C. Le Deley, M.-M. Ruchoux, D. Couanet, F. Doz, F. Pichon, H. Rubie, D. Frappaz, J.-P. Vannier, et al.
Progression-Free Survival in Children With Optic Pathway Tumors: Dependence on Age and the Quality of the Response to Chemotherapy--Results of the First French Prospective Study for the French Society of Pediatric Oncology
J. Clin. Oncol.,
December 15, 2003;
21(24):
4572 - 4578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pace, A. Vidiri, E. Galie, M. Carosi, S. Telera, A. M. Cianciulli, P. Canalini, D. Giannarelli, B. Jandolo, and C. M. Carapella
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response
Ann. Onc.,
December 1, 2003;
14(12):
1722 - 1726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
